Patents by Inventor Tomoyuki Tsunemi

Tomoyuki Tsunemi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10933065
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: March 2, 2021
    Assignee: ArQule Inc.
    Inventors: Jean-Marc Lapierre, Sudharshan Eathiraj, Nivedita Namdev, Brian Schwartz, Yusuke Ota, Takayuki Momose, Tomoyuki Tsunemi, Hiroaki Inagaki, Kiyoshi Nakayama
  • Publication number: 20200061071
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Application
    Filed: November 4, 2019
    Publication date: February 27, 2020
    Inventors: Jean-Marc LAPIERRE, Sudharshan EATHIRAJ, Nivedita NAMDEV, Brian SCHWARTZ, Yusuke OTA, Takayuki MOMOSE, Tomoyuki TSUNEMI, Hiroaki INAGAKI, Kiyoshi NAKAYAMA
  • Publication number: 20190358233
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of BTK, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Application
    Filed: August 5, 2019
    Publication date: November 28, 2019
    Inventors: Craig BATES, Sudharshan Eathiraj, Hiroaki Inagaki, Jean-Marc Lapierre, Takayuki Momose, Kiyoshi Nakayama, Takashi Odagiri, Masahiro Ota, Yusuke Ota, Yoshihiro Shibata, Manish Tandon, Tomoyuki Tsunemi
  • Publication number: 20190192520
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Application
    Filed: March 4, 2019
    Publication date: June 27, 2019
    Inventors: Jean-Marc LAPIERRE, Sudharshan EATHIRAJ, Nivedita NAMDEV, Brian SCHWARTZ, Yusuke OTA, Takayuki MOMOSE, Tomoyuki TSUNEMI, Hiroaki INAGAKI, Kiyoshi NAKAYAMA
  • Patent number: 10245263
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: April 2, 2019
    Assignee: ArQule, Inc.
    Inventors: Jean-Marc Lapierre, Sudharshan Eathiraj, Nivedita Namdev, Brian Schwartz, Yusuke Ota, Takayuki Momose, Tomoyuki Tsunemi, Hiroaki Inagaki, Kiyoshi Nakayama
  • Publication number: 20180055846
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of BTK, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Application
    Filed: August 23, 2017
    Publication date: March 1, 2018
    Inventors: Craig BATES, Sudharshan Eathiraj, Hiroaki Inagaki, Jean-Marc Lapierre, Takayuki Momose, Kiyoshi Nakayama, Takashi Odagiri, Masahiro Ota, Yusuke Ota, Yoshihiro Shibata, Manish Tandon, Tomoyuki Tsunemi
  • Publication number: 20170182053
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Application
    Filed: March 3, 2017
    Publication date: June 29, 2017
    Inventors: Jean-Marc LAPIERRE, Sudharshan EATHIRAJ, Nivedita NAMDEV, Brian SCHWARTZ, Yusuke OTA, Takayuki MOMOSE, Tomoyuki TSUNEMI, Hiroaki INAGAKI, Kiyoshi NAKAYAMA
  • Patent number: 9630968
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: April 25, 2017
    Assignee: ArQule, Inc.
    Inventors: Jean-Marc Lapierre, Sudharshan Eathiraj, Nivedita Namdev, Brian Schwartz, Yusuke Ota, Takayuki Momose, Tomoyuki Tsunemi, Hiroaki Inagaki, Kiyoshi Nakayama
  • Patent number: 8785438
    Abstract: A compound represented by formula (I) having mTOR inhibitory activity or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: July 22, 2014
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Masami Ohtsuka, Noriyasu Haginoya, Masanori Ichikawa, Hironori Matsunaga, Hironao Saito, Yoshihiro Shibata, Tomoyuki Tsunemi
  • Patent number: 8436012
    Abstract: A compound represented by formula (I) having mTOR inhibitory activity or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: May 7, 2013
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Masami Ohtsuka, Noriyasu Haginoya, Masanori Ichikawa, Hironori Matsunaga, Hironao Saito, Yoshihiro Shibata, Tomoyuki Tsunemi
  • Publication number: 20110082138
    Abstract: A compound represented by formula (I) having mTOR inhibitory activity or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: November 24, 2010
    Publication date: April 7, 2011
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Masami Ohtsuka, Noriyasu Haginoya, Masanori Ichikawa, Hironori Matsunaga, Hironao Saito, Yoshihiro Shibata, Tomoyuki Tsunemi